Development and optimization of anti-HIV nucleoside analogs and prodrugs:: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics

Abstract

Significant improvements in antiviral therapy have been realized over the past 10 years. Numerous nucleoside analogs, as well as prodrugs of active compounds, have been synthesized and tested for anti-HIV activity. In addition to the five nucleoside analogs currently used clinically for the treatment of HIV infection, a broad spectrum of anti-HIV nucleoside analogs (including 2′,3′-dideoxynucleoside analogs, oxathiolanyl 2′,3′-dideoxynucleoside analogs, dioxolanyl 2′,3′-dideoxynucleoside analogs, carbocyclic 2′,3′-dideoxynucleoside analogs and acyclic nucleoside analogs) and their prodrugs (including ester prodrugs, phospholipid prodrugs, dihydropyridine prodrugs, pronucleotides and dinucleotide analogs), targeted at HIV reverse transcriptase, are reviewed with focus on structure-activity relationships, cellular pharmacology and pharmacokinetics. Several of these anti-viral agents show promise in the treatment of AIDS.